Silver Book Fact

Antihypertensive treatment has generated a benefit-to-cost ratio of at least 6:1 (6:1 in women and 10:1 in men).

Cutler D, Long G, Berndt E, Royer J, et al. The Value Of Antihypertensive Drugs: A perspective on medical innovation. Health Affairs. 2007; 26(1): 97-110

Reference

Title
The Value Of Antihypertensive Drugs: A perspective on medical innovation
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Cutler D, Long G, Berndt E, Royer J, et al.
Volume & Issue
Volume 26, Issue 1
Pages
97-110

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Between 1998 and 2008, the rate of death attributable to cardiovascular disease declined 30.6%.  
  • Anti-platelet therapy stroke risk reduction
    Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.  
  • Medicines Produce Valuable Health Gains for Heart Attack Patients  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.